| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Addition of Elotuzumab to Backbone Treatment Regimens for Multiple Myeloma: An Updated Meta-Analysis of Randomized Clinical Trials
|
Costa, Bruno Almeida
|
|
|
25 |
1 |
p. 32-44
|
artikel
|
| 2 |
Analysis of Histologic, Immunohistochemical and Genomic Features of Large B Cell Lymphoma Tumors May Predict Response to Polatuzumab Vedotin Based Therapy in Patients With Relapsed/Refractory Disease
|
Schneider, Michael
|
|
|
25 |
1 |
p. 45-51
|
artikel
|
| 3 |
A Real-World Analysis on Access to Triplet and Quadruplet Therapy in Newly Diagnosed Multiple Myeloma Patients in the United States
|
Saba, Ludovic
|
|
|
25 |
1 |
p. e1-e10
|
artikel
|
| 4 |
BCMA-Directed MRD Detection as a Predictor of Relapse after BCMA CAR T in Multiple Myeloma
|
Rashid, Aliya
|
|
|
25 |
1 |
p. 52-57
|
artikel
|
| 5 |
Brazilian Real-Life Experience of Multiple Myeloma (MMyBRAve): Improvement in Outcomes, But Remaining Diagnostic and Therapeutic Gaps
|
Hungria, Vania
|
|
|
25 |
1 |
p. 26-31
|
artikel
|
| 6 |
CD10-Positive Lymphoplasmacytic Lymphoma: A Diagnostic Pitfall
|
Ju, Yaping
|
|
|
25 |
1 |
p. 23-25
|
artikel
|
| 7 |
Characteristics and Treatment Patterns of Long-surviving Patients With Multiple Myeloma: Over 13 Years of Follow-up in the ConnectⓇ MM Registry
|
Terebelo, Howard R.
|
|
|
25 |
1 |
p. 58-66
|
artikel
|
| 8 |
Clinical Characteristics and Survival Outcomes of Patients With Primary and Secondary Plasma Cell Leukemia According to the 2021 Definition: A Single Center Retrospective Study
|
Shalaby, Khalid
|
|
|
25 |
1 |
p. 67-75
|
artikel
|
| 9 |
Comparison of Long-Term Outcomes of Double Unit Cord Blood Versus Haploidentical Donor Transplantation in Adult Patients With Acute Lymphoblastic Leukemia Regarding KIR-Ligand Mismatch
|
Lee, Seonghan
|
|
|
25 |
1 |
p. e11-e25.e1
|
artikel
|
| 10 |
DA-R-EPOCH May Mitigate the Adverse Prognostic Implication of the Diagnosis-to-Treatment Interval (DTI) in Large B-Cell Lymphomas
|
Allen, Jessica
|
|
|
25 |
1 |
p. e26-e33
|
artikel
|
| 11 |
Deep Molecular Response Rate in Chronic Phase Chronic Myeloid Leukemia: Eligibility to Discontinuation Related to Time to Response and Different Frontline TKI in the Experience of the Gimema Labnet CML National Network
|
Breccia, Massimo
|
|
|
25 |
1 |
p. e34-e39
|
artikel
|
| 12 |
Dementia Incidence in Survivors of Multiple Myeloma: A National Case-Control Study Conducted in Korea (The CAREMM-2106 Study)
|
Ha, Jeonghoon
|
|
|
25 |
1 |
p. e40-e49
|
artikel
|
| 13 |
Discontinuation of Tyrosine Kinase Inhibitor Therapy and Treatment Free Remission (TFR) in Chronic Myeloid Leukemia: Successful Achievement of TFR in More Than Two-Third of Patients in a Real-World Practice
|
Aleem, Aamer
|
|
|
25 |
1 |
p. e50-e56
|
artikel
|
| 14 |
Editorial Board
|
|
|
|
25 |
1 |
p. A1-A2
|
artikel
|
| 15 |
Efficacy and Safety of the First-in-Class STAMP-Inhibitor Asciminib in Patients With Chronic Myeloid Leukemia
|
Ureshino, Hiroshi
|
|
|
25 |
1 |
p. e57-e61
|
artikel
|
| 16 |
Estimated Financial Savings From Clinical Studies at Oslo Myeloma Center in the Period 2015-2021
|
Hamnvik, Lars Henrik Dahl
|
|
|
25 |
1 |
p. e62-e69
|
artikel
|
| 17 |
SOHO State of the Art Update and Next Questions: Current and Emerging Therapies for Systemic Mastocytosis
|
Chifotides, Helen T.
|
|
|
25 |
1 |
p. 1-12
|
artikel
|
| 18 |
SOHO State of the Art Updates and Next Questions | Approach to BCR::ABL1-Like Acute Lymphoblastic Leukemia
|
Iacobucci, Ilaria
|
|
|
25 |
1 |
p. 13-22
|
artikel
|
| 19 |
Table of Contents
|
|
|
|
25 |
1 |
p. A3-A5
|
artikel
|
Tijdschrift beschrijving